Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Rubius rapeutics

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · Sep 14, 2022

What 6 Analyst Ratings Have To Say About Rubius Therapeutics

Over the past 3 months, 6 analysts have published their opinion on Rubius Therapeutics (NASDAQ:RUBY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · May 10, 2022

12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga · Apr 25, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga · Apr 21, 2022

Expert Ratings for Rubius Therapeutics

Over the past 3 months, 5 analysts have published their opinion on Rubius Therapeutics (NASDAQ:RUBY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Apr 11, 2022

SVB Leerink Maintains Market Perform Rating for Rubius Therapeutics, Lowers Price Target To $3

SVB Leerink has decided to maintain its Market Perform rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $5.00 to $3.00. Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

Benzinga · Apr 11, 2022

Guggenheim Maintains Buy Rating for Rubius Therapeutics, Lowers Price Target To $5

Guggenheim has decided to maintain its Buy rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $25.00 to $5.00. Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

Benzinga · Apr 11, 2022

Read news from The Economist, FT, and more,
with one subscription

12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga · Apr 8, 2022

Rubius Therapeutics Earnings Preview

Rubius Therapeutics (NASDAQ:RUBY) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts estimate that Rubius Therapeutics will report an earnings per share (EPS) of $-0.59.

Benzinga · Feb 24, 2022

Coverage From

Benzinga

Organisations

Rhythm Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.